# Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

> **NCT03350295** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 48 (actual)

## Conditions studied

- Chagas Disease

## Interventions

- **DRUG:** Nifurtimox (Lampit, BAYA2502)

## Key facts

- **NCT ID:** NCT03350295
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-14
- **Primary completion:** 2018-09-18
- **Final completion:** 2018-12-14
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03350295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03350295, "Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03350295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*